Enduring Materials

Access slide decks and video via the links in the schedule below.

PDF = PDF of slides is available

= Presentation video is available

Program Schedule Friday, November 11, 2016
7:30 a.m. – 7:35 a.m.	Presidential Welcome Howard L. Kaufman, MD, FACS – Rutgers Cancer Center Institute of New Jersey
7:35 a.m. – 8:00 a.m.	Holbrook Edwin Kidd Kohrt, MD, PhD Tribute* Non-CE Session Co-Chairs: Daniel S. Chen, MD, PhD – Genentech Amani Makkouk, PhD – Calithera Biosciences Ignacio Melero, MD, PhD – University of Navarra Russell Pachynski, MD – Washington University School of Medicine
Update Session: Cancer Immunotherapy Trials Network (CITN): Ten Trials with High Priority Agents in Twenty Five Minutes 0.25 AMA PRA Category 1 Credits^TM Chair: Martin Cheever, MD – Fred Hutchinson Cancer Research Center
8:00 a.m. – 8:05 a.m.	Anti-PD1 in Merkel Cell Cancer and in Malignancy with HIV, IL7 in Prostate Cancer, Anti-CD40 in Pancreas Cancer Martin Cheever, MD – Fred Hutchinson Cancer Research Center
8:05 a.m. – 8:10 a.m.	Anti-PD1 in Mycosis Fungoides/Sezary Syndrome Michael Khodadoust, MD – Stanford University
8:10 a.m. – 8:15 a.m.	IL15 in Solid Tumors Jeffrey S. Miller, MD – University of Minnesota
8:15 a.m. – 8:20 a.m.	IDO Inhibitor in Ovarian Cancer and Melanoma Kunle Odunsi, MD, PhD – Roswell Park Cancer Institute Center for Immunotherapy
8:20 a.m. – 8:25 a.m.	Flt3-L with Poly ICLC and Anti-DEC205-NY-ESO-1 in Melanoma Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Mount Sinai Medical Center
Keynote Address Non-CE Session
8:25 a.m. – 8:30 a.m.	Introduction Howard L. Kaufman, MD, FACS – Rutgers Cancer Center Institute of New Jersey
8:30 a.m. – 9:05 a.m.	The Mechanistic Basis of Cancer Immunotherapy Ira Mellman, PhD – Genentech
9:05 a.m. – 9:10 a.m.	Question & Answer Ira Mellman, PhD – Genentech
Tumor Microenvironment 2.25 AMA PRA Category 1 Credits™ Co-Chairs: Mary L. (Nora) Disis, MD – University of Washington Thomas F. Gajewski, MD, PhD – University of Chicago
9:10 a.m. – 9:15 a.m.	Introduction Co-Chair & Faculty: Mary (Nora) L. Disis, MD – University of Washington
9:15 a.m. – 9:40 a.m.	Tumor Microenvironment with Clinical Aspect; Impact of Therapeutics on Microenvironment George Coukos, MD, PhD – University Hospital of Lausanne
9:40 a.m. – 10:05 a.m.	Immunomodulatory Roles of Lymphatic Vessels in the Tumor Microenvironment Melody Swartz, PhD – University of Chicago
10:25 a.m. – 10:50 a.m.	CD4 T Cells as Regulators of Tumor Growth Mary (Nora) L. Disis, MD – University of Washington
10:50 a.m. – 11:05 a.m.	Neuropilin-1-Deficient Regulatory T Cell-Derived Interferon-γ Drives Infectious Instability and Tumor Clearance Abigail E. Overacre – University of Pittsburgh
11:05 a.m. – 11:30 a.m.	Tumor and Host Factors Influencing Immune Regulation Within the Tumor Microenvironment Thomas F. Gajewski, MD, PhD – University of Chicago
11:30 a.m. – 11:45 a.m.	CD8α+ Dendritic Cells Regulate Leukemia Antigen-Specific CD8+ T Cell Tolerance Justin P. Kline, MD – University of Chicago
Late-Breaking Abstract Session I Non-CE Session Chair: Laura S. Wood, RN, MSN OCN – Cleveland Clinic Taussig Cancer Institute
11:45 a.m. – 12:00 a.m.	Computational Identification, Functional Characterization and Antibody Blockade of a New Immune Checkpoint in the TIGIT Family of Interacting Molecules John Hunter, PhD – Compugen USA, Inc.
12:00 p.m. – 12:15 p.m.	Combinatorial CD8+ and PD-L1 + Cell Densities Correlate with Response and Improved Survival in NSCLC Patients Treated with Durvalumab Sonja Althammer, PhD – Definiens AG
Update Session: Government Agencies 0.5 AMA PRA Category 1 Credits™ Chair: James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
1:30 p.m. – 1:45 p.m.	National Cancer Institute T. Kevin Howcroft, PhD – National Cancer Institute, National Institutes of Health
1:45 p.m. – 2:00 p.m.	U.S. Food & Drug Administration Raj K. Puri, MD, PhD – U.S. Food & Drug Administration
State-of-the-Art Immunotherapies: Challenges and Opportunities 2.25 AMA PRA Category 1 Credits™ Co-Chairs: James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health Roy S. Herbst, MD, PhD – Yale Cancer Center
2:00 p.m. – 2:05 p.m.	Introduction James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Heath
2:05 p.m. – 2:30 p.m.	Challenges and Opportunities for Immunotherapy in Prostate Cancer James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
2:30 p.m. – 2:55 p.m.	Melanoma: Challenges and Opportunities and the Need for Rational Combinations of Agents Patrick Hwu, MD – University of Texas MD Anderson Cancer Center
2:55 p.m. – 3:05 p.m.	Phase I/II CANON Study: Oncolytic Immunotherapy for the Treatment of Non-Muscle Invasive Bladder (NMIBC) Cancer Using Intravesical Coxsackievirus A21 Nicola E. Annels, BSc, PhD – University of Surrey
3:05 p.m. – 3:15 p.m.	IL-15 Primes an mTOR-Regulated Gene-expression Program to Prolong Anti-tumor Capacity of Human Natural Killer Cells Andreas Lundqvist – Karolinska Institutet
3:15 p.m. – 3:25 p.m.	Reactivating the Anti-Tumor Immune Response by Targeting Innate and Adaptive Immunity in a Phase I/II Study of Intratumoral IMO-2125 in Combination with Systemic Ipilimumab in Patients with Anti-PD-1 Refractory Metastatic Melanoma Cara Haymaker, PhD – University of Texas MD Anderson Cancer Center
3:25 p.m. – 3:50 p.m.	Translational Development of Novel Immunotherapies for Hematologic Cancers Larry W. Kwak, MD, PhD – City of Hope National Medical Center
3:50 p.m. – 4:15 p.m.	Lung Cancer: Frontline Therapy, Predictive Markers, and Novel Combinations Roy S. Herbst, MD, PhD – Yale Cancer Center
Concurrent Session 1: Metabolic and Age-Associated Dysregulation of Anti-Cancer Immunity 1.5 AMA PRA Category 1 Credits™ Organized in collaboration with the American Society for Cell Biology (ASCB) Co-Chairs: Tom Misteli, PhD – National Cancer Institute, National Institutes of Health Graham P. Pawelec, PhD – University of Tuebingen
4:45 p.m. – 4:50 p.m.	Introduction Graham P. Pawelec, PhD – University of Tuebingen
4:50 p.m. – 5:15 p.m.	The Immune System Strikes Back: T Cells Recognizing Indoleamine 2,3-Dioxygenase (IDO) or PD-L1 Mads Hald Andersen, PhD – Herlev University Hospital
5:15 p.m. – 5:40 p.m.	Myeloid-Derived Suppressor Cells (MDSC), Age and Cancer Dawn Bowdish, PhD – McMaster University
5:40 p.m. – 5:55 p.m.	NAD-Sirt1 Axis is Central to the Unique Immuno-Metabolic Phenotype of Th1/17 Hybrid Cells in Regulating its Enhanced Anti-Tumor Potential Shilpak Chatterjee, PhD – Medical University of South Carolina
5:55 p.m. – 6:10 p.m.	The Wnt5a-Beta-Catenin Pathway Triggers a Metabolic Switch that Drives Indoleamine 2,3-Dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment: Optimizing Checkpoint Inhibitor Immunotherapy Brent A. Hanks, MD, PhD – Duke University Medical Center
Concurrent Session II: Promoting and Measuring Anti-Tumor Immunity 1.25 AMA PRA Category 1 Credits™ Co-Chairs: Francesco M. Marincola, MD – Sidra Medical and Research Center Jeffrey Schlom, PhD – National Cancer Institute, National Institutes of Health
4:45 p.m. – 4:50 p.m.	Introduction Jeffrey Schlom, PhD – National Cancer Institute, National Institutes of Health
4:50 p.m. – 5:10 p.m.	Immunotherapeutics and Analyses of the Peripheral Immunome Jeffrey Schlom, PhD – National Cancer Institute, National Institutes of Health
5:10 p.m. – 5:30 p.m.	Vaccines, Tumor Antigens, and Immune Responses Lisa H. Butterfield, PhD – University of Pittsburgh
5:30 p.m. – 5:50 p.m.	Deciphering Human T Cell Immune Responses Modulated with Immunotherapy Lawrence Fong, MD – University of California, San Francisco
5:50 p.m. – 6:05 p.m.	Immunoscore® Colon Analytical Performance Fabienne Hermitte, PhD – HalioDx
6:05 p.m. – 6:10 p.m.	Closing Remarks Francesco M. Marincola, MD – Sidra Medical and Research Center
Saturday, November 12, 2016
Update Session: Society Initiatives
7:30 AM – 7:40 AM	Immune Biomarkers Task Force Update Lisa H. Butterfield, PhD – University of Pittsburgh
7:40 AM – 7:55 AM	Immunoscore as a Prognostic Marker in Stage I-III Colon Cancer: Results of a SITC-Led Global Validation Study Jérôme Galon, PhD – INSERM – Cordeliers Research Center
Richard Smalley, MD Memorial Lectureship .75 AMA PRA Category 1 Credits™
7:55 a.m. – 8:00 a.m.	Introduction Howard L. Kaufman, MD, FACS – Rutgers Cancer Center Institute of New Jersey
8:00 a.m. – 8:35 a.m.	Smalley Keynote Address: PD-1 Blockade in Cancer Treatment – Immunotherapy Meets Precision Medicine Suzanne L. Topalian, MD – Johns Hopkins University
8:35 a.m. – 8:40 a.m.	Question & Answer Suzanne L. Topalian, MD – Johns Hopkins University
Beyond Single-Agents: The Future of Combination Immunotherapy 2.0 AMA PRA Category 1 Credits™ Co-Chairs: Drew M. Pardoll, MD, PhD – Johns Hopkins University F. Stephen Hodi, MD – Dana-Farber Cancer Institute Holbrook E. Kohrt, MD, PhD– Stanford Cancer Institute*
8:40 a.m. – 8:45 a.m.	Introduction F. Stephen Hodi, MD – Dana-Farber Cancer Institute
8:45 a.m. – 9:10 a.m.	Combination Development Ignacio Melero, MD, PhD – University of Navarra
9:10 a.m. – 9:35 a.m.	Next Generation Anti-CTLA-4 Antibodies Alan J. Korman, PhD – Bristol-Myers Squibb Company
9:35 a.m. – 10:00 a.m.	Combination in Patient Selection Jérôme Galon, PhD – INSERM – Cordeliers Research Center
10:20 a.m.– 10:40 a.m.	Combinations and Influences on Biomarkers Drew M. Pardoll, MD, PhD – Johns Hopkins University
10:40 a.m. – 10:55 a.m.	Clinical Safety and Efficacy Assessment of the CD137 Agonist Urelumab Alone and in Combination with Nivolumab in Patients with Hematologic and Solid Tumor Malignancies Erminia Massarelli, MD – MD Anderson Cancer Center, University of Texas
10:55 a.m. – 11:10 a.m.	Beyond Immune Checkpoint: First-in-Class Antibody Targeting Soluble NKG2D Ligand sMIC for Cancer Immunotherapy Jennifer Wu, PhD – Medical University of South Carolina
11:10 a.m. – 11:15 a.m.	Closing Remarks Drew M. Pardoll, MD, PhD – Johns Hopkins University
Late-Breaking Abstract Session II Non-CE Session Chair: Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute
11:15 a.m. – 11:30 a.m.	Preliminary Efficacy from a Phase 1/2 Study of the Natural Killer Cell-Targeted Antibody, Lirilumab in Combination with Nivolumab in Squamous Cell Carcinoma of the Head and Neck Rom Leidner, MD – Earl A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Center
11:30 a.m. – 11:45 a.m.	Efficacy and Safety of Nivolumab Plus Ipilimumab in Metastatic Urothelial Carcinoma: First Results From the Phase I/II From the Phase I/II CheckMate 032 Study Padmanee Sharma, MD, PhD – University of Texas MD Anderson Cancer Center
11:45 a.m. – 12:00 p.m.	KEYNOTE-045: Open-label, Phase 3 Study of Pembrolizumab versus Investigator’s Choice of Paclitaxel, Docetaxel, or Vinflunine for Previously Treated Advanced Urothelial Cancer Joaquim Bellmunt, MD, PhD – Dana-Farber Cancer Institute
Concurrent Session I: Presidential Session 1.25 AMA PRA Category 1 Credits™ Chair: Howard L. Kaufman, MD, FACS – Rutgers Cancer Center Institute of New Jersey
1:00 p.m. – 1:05 p.m.	Introduction Howard L. Kaufman, MD, FACS – Rutgers Cancer Center Institute of New Jersey
1:05 p.m. – 1:20 p.m.	Intestinal Microbiota and Relapse after Hematopoietic-Cell Transplantation Jonathan Peled, MD, PhD – Memorial Sloan Kettering Cancer Center
1:20 p.m. – 1:35 p.m.	Mitochondrial Biogenesis is Repressed in Tumor-Infiltrating CD8+ T Cells Resulting in Metabolic Insufficiency and T Cell Dysfunction Nicole E. Scharping – University of Pittsburgh
1:35 p.m. – 1:45 p.m.	Expert Discussant Drew M. Pardoll, MD, PhD – Johns Hopkins University
1:45 p.m. – 2:00 p.m.	Increased STAT3 Signaling and Decreased Suppressive Function of Regulatory T Cells are Biomarkers of Positive Patient Outcome to Nivolumab Therapy David M. Woods, PhD – New York University
2:00 p.m. – 2:15 p.m.	Analysis of Pharmacodynamic Biomarkers in the First In-Human Trial of GITR Co-Stimulation with the Agonist Antibody TRX-518 in Advanced Solid Cancer Patients Roberta Zappasodi, PhD – Memorial Sloan Kettering Cancer Center
2:15 p.m. – 2:25 p.m.	Expert Discussant Jeffrey Schlom, PhD – National Cancer Institute, National Institutes of Health
Concurrent Session II: Tumor Immunology 101 (Nurse/Pharmacist Track) 1.5 AMA PRA Category 1 Credits™ Co-Chairs: Satiro N. De Oliveira, MD – University of California, Los Angeles Paul M. Sondel, MD, PhD – University of Wisconsin, Madison
1:00 p.m. – 1:05 p.m.	Introduction Paul M. Sondel, MD, PhD – University of Wisconsin, Madison
1:05 p.m. – 1:30 p.m.	Immunology 101 for the Non-Immunologist Christian Capitini, MD – University of Wisconsin, Madison
1:30 p.m. – 1:55 p.m.	Basic Principles of Tumor Immunotherapy Satiro N. De Oliveira, MD – University of California Los Angeles
1:55 p.m. – 2:20 p.m.	Tumor Immunotherapy on the Horizon Paul M. Sondel, MD, PhD – University of Wisconsin, Madison
2:20 p.m.– 2:25 p.m.	Closing Remarks Satiro N. De Oliveira, MD – University of California Los Angeles
Concurrent Session I: Microbiome and the Impact on Local Inflammation and Host Immunity 1.75 AMA PRA Category 1 Credits™ Co-Chairs: Lisa M. Coussens, PhD – Oregon Health and Science University Heidi H. Kong, MD, MHSc – National Cancer Institute, National Institutes of Health
2:40 p.m. – 2:45 p.m.	Introduction Heidi H. Kong, MD, MHSc – National Cancer Institute, National Institutes of Health
2:45 p.m. – 3:10 p.m.	Microbial Modulation of Mononuclear Phagocytes in Cancer Therapy Romina Goldszmid, PhD – National Cancer Institute, National Institutes of Health
3:10 p.m. – 3:35 p.m.	Influence of Microbiome on Efficacy of Anti-Cancer Chemotherapy María Paula Roberti, PhD – Institute Gustave Roussy
3:35 p.m. – 4:00 p.m.	Inflammation Fuels Microbial Carcinogenic Activities Christian Jobin, PhD – University of Florida
4:00 p.m. – 4:15 p.m.	Pre-Existing Immunity to Oncolytic Virus Potentiates its Therapeutic Efficacy Jacob Ricca – Memorial Sloan Kettering Cancer Center
4:15 p.m. – 4:20 p.m.	Closing Remarks Lisa M. Coussens, PhD – Oregon Health and Science University
Concurrent Session II: Clinical Management (Nurse/Pharmacist Track) 1.75 AMA PRA Category 1 Credits™ Co-Chairs: Matthew Burke, MBA, RN, MSN, APRN-B – Stanford Health Care Laura S. Wood, RN, MSN OCN – Cleveland Clinic Taussig Cancer Institute
2:40 p.m. – 2:45 p.m.	Introduction Laura S. Wood, RN, MSN OCN – Cleveland Clinic Taussig Cancer Institute
2:45 p.m. – 3:05 p.m.	Immunotherapy Agents Currently Approved for the Treatment of Cancer Kristen Kreamer, CRNP, MSN, AOCNP, APRN-BC – Fox Chase Cancer Center
3:05 p.m. – 3:25 p.m.	Assessment & Management of irAEs Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital Cancer Center
3:25 p.m. – 3:45 p.m.	Management of Complex Adverse Events: Case Studies Brianna W. Hoffner, BA, MSN, RN, ANP-BC – University of Colorado Cancer Center
3:45 p.m. – 4:00 p.m.	Incidence and Outcomes of Central Nervous System Metastasis in Metastatic Melanoma Patients Treated with Anti-PD1 Therapy Gustavo Schvartsman, MD – University of Texas MD Anderson Cancer Center
4:00 p.m. – 4:15 p.m.	Audience Question & Answer Moderator: Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
4:15 p.m. – 4:20 p.m.	Closing Remarks Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
Concurrent Session I: Diet, Exercise, Stress and the Impact on the Immune System 1.5 AMA PRA Category 1 Credits™ Organized in collaboration with the Society of Behavioral Medicine (SBM) Co-Chairs: Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute Connie J. Rogers, PhD, MPH – Pennsylvania State University
4:50 p.m. – 4:55 p.m.	Introduction Connie J. Rogers, PhD, MPH – Pennsylvania State University
4:55 p.m. – 5:15 p.m.	Changes in Energy Balance Modulate the Immune Response in Breast Cancer Risk & Progression Connie J. Rogers, PhD, MPH – Pennsylvania State University
5:15 p.m. – 5:35 p.m.	Research in Behavior in Cancer and Cancer Treatment Dana H. Bovbjerg, PhD – University of Pittsburgh Cancer Institute
5:35 p.m. – 5:55 p.m.	Effects of Behavioral Stress on the Tumor Microenvironment Susan K. Lutgendorf, PhD – University of Iowa
5:55 p.m. – 6:10 p.m.	β-Adrenergic Signaling Induced by Cool Housing Temperatures Mediates Immune Suppression and Impairs the Efficacy of Anti-PD-1 Checkpoint Blockade Immunotherapy in Laboratory Mice Mark J. Bucsek – Roswell Park Cancer Institute
6:10 p.m. – 6:15 p.m.	Closing Remarks Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute
Concurrent Session II: Adoptive Cellular Therapy vs. Bispecific Antibodies 1.5 AMA PRA Category 1 Credits™ Co-Chairs: Crystal L. Mackall, MD – Stanford University Stanley R. Riddell, MD – Fred Hutchinson Cancer Research Center
4:50 p.m. – 4:55 p.m.	Introduction Crystal L. Mackall, MD – Stanford University
4:55 p.m. – 5:15 p.m.	CARs - CD19 and Beyond Crystal L. Mackall, MD – Stanford University
5:15 p.m. – 5:35 p.m.	Bispecific T Cell Engagers, Biology and Clinical Application Max S. Topp, MD – Universitatsklinikum Wurzburg
5:35 p.m. – 5:55 p.m.	CAR Designs for Safe and Effective T Cell Therapy Stanley R. Riddell, MD – Fred Hutchinson Cancer Research Center
5:55 p.m. – 6:10 p.m.	Clinical Responses in Advanced Pancreatic Patients Treated with Bispecific Antibody Armed T Cells (BATS) Lawrence G. Lum, MD, DSc – University of Virginia Cancer Center
6:10 p.m. – 6:15 p.m.	Closing Remarks Stanley R. Riddell, MD – Fred Hutchinson Cancer Research Center
Concurrent Session III: Emerging Technologies Non-CE Session Co-Chairs: Edward C. Stack, PhD – PerkinElmer David A. Zaharoff, PhD – University of North Carolina, Chapel Hill & North Carolina State University
4:50 p.m. – 4:55 p.m.	Introduction Edward C. Stack, PhD – PerkinElmer
4:55 p.m. – 5:20 p.m.	Understanding T Cells, Macrophages, and Expression of PD-1/PD-L1 in Hodgkin's Lymphoma Scott J. Rodig, MD, PhD – Brigham and Women's Hospital, Harvard Medical School
5:20 p.m. – 5:40 p.m.	Eradication of Large Established Tumors by Combination Immunotherapy Engaging Innate and Adaptive Immunity Darrell J. Irvine, PhD – Massachusetts Institute of Technology
5:40 p.m. – 5:55 p.m.	Mechanisms of Chitosan/IL-12 Immunotherapy for the Treatment of Bladder Cancer Sean G. Smith – University of North Carolina - Chapel Hill & North Carolina State University
5:55 p.m. – 6:10 p.m.	ImmunoMap: A Novel Bioinformatics Tool for Analysis of T Cell Receptor Repertoire Data in Model Systems and Clinical Settings John-William Sidhom – Johns Hopkins University
6:10 p.m. – 6:15 p.m.	Closing Remarks David A. Zaharoff, PhD – University of North Carolina - Chapel Hill & North Carolina State University
Sunday, November 13, 2016
7:45 a.m. – 7:50 a.m.	Annual Meeting Organizer Welcome James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
7:50 a.m. – 8:00 a.m.	Program Introduction Howard L. Kaufman, MD, FACS – Rutgers Cancer Center Institute of New Jersey
Session I: Current Landscape of Cancer Therapy Value Models, Economic Outcomes, and the Patient Perspective
8:00 a.m. – 8:30 a.m.	Evaluation of Current Value Models Peter P. Yu, MD, FACP, FASCO – Hartford HealthCare Cancer Institute
8:30 a.m. – 8:45 a.m.	Cancer Immunotherapy Perspective on Current Value Models Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
8:45 a.m. – 9:05 a.m.	Economic Outcomes of Cancer Therapy: ISPOR Initiative on U.S. Value Assessment Framework Louis Garrison, PhD, AB – University of Washington
9:05 a.m. – 9:25 a.m.	Patient Perspective Steven Silverstein, MBA – Melanoma Research Foundation
9:25 a.m. – 9:45 a.m.	Patient Outcomes Perspective: Patient Reported Outcomes & Personal Cost of Cancer Adam P. Dicker, MD, PhD – Thomas Jefferson University Heather S. Jim, PhD – H. Lee Moffitt Cancer Center & Research Institute
9:45 a.m. – 10:10 a.m.	Panel Discussion Moderator: Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey Panelists: Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center Adam P. Dicker, MD, PhD – Thomas Jefferson University Lou Garrison, PhD, AB – University of Washington Heather S. Jim, PhD – H. Lee Moffitt Cancer Center & Research Institute Steven Silverstein, MBA – Melanoma Research Foundation Peter P. Yu, MD, FACP, FASCO – Hartford HealthCare Cancer Institute
Session II: Perspectives on the Value of Cancer Immunotherapy
10:10 a.m. – 10:30 a.m.	Payor Perspective William McGivney, PhD – McGivney Global Advisors
10:30 a.m. – 10:50 a.m.	Industry Perspective Jon M. Wigginton, MD – MacroGenics, Inc.
10:50 a.m. – 11:10 a.m.	Predictive and Companion Biomarkers Roy S. Herbst, MD, PhD – Yale Cancer Center
11:10 a.m. – 11:55 a.m.	Panel Discussion Moderator: Michael B. Atkins, MD – Kirsten Axelsen, MS – Pfizer Daniel S. Chen, MD, PhD – Genentech Ravinder Dhawan, PhD – Merck & Co Roy S. Herbst, MD, PhD – Yale Cancer Center Gregory Keenan, MD – AstraZeneca William McGivney, PhD – McGivney Global Advisors Jon M. Wigginton, MD – MacroGenics, Inc.
11:55 a.m. – 12:00 p.m.	Closing Remarks